ADDOXXO ALDOX

UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No. PC10893AGPR

First Named Inventor or Application Identifier T

Title The Canine Androgen Receptor

Express Mail Label No. EL911724455US

<u></u>	
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.	ADDRESS TO: Assistant Commissioner for Patents D Box Patent Application
K 7	Washington, DC 20231
 *Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original, and a duplicate for fee processing) 	Microfiche Computer Program (Appendix)
2. Specification [Total Pages [23]] (preferred arrangement set forth below)	 Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
- Descriptive title of the Invention	a. Computer Readable Copy
- Cross References to Related Applications	b. Paper Copy (identical to computer copy)
 Statement Regarding Fed sponsored R&D Reference in Microfiche Appendix 	c. Statement verifying identity of above copies
- Background of the Invention	ACCOMPANYING APPLICATION PARTS
- Brief Summary of the Invention	Assignment Papers (cover sheet & document(s))
Brief Description of the Drawings (if filed) Detailed Description	
- Claim(s)	9 37 C.F.R. §3.73(b) Statement Power of Attorney (when there is an assignee)
- Abstract of the Disclosure	10. English Translation Document (if applicable)
• =	11. Information Disclosure Copies of IDS
3. Drawing(s) (35 U.S.C. 11.3)[Total sheets	Statement (IDS)/PTO-1449 Citations
Oath or Declaration [Total pages 3]	12. Preliminary Amendment
a. Newly executed (original or copy)	13. Return Receipt Postcard (MPEP 503)
b. Copy from a prior application (37 CFR	(Should be specifically itemized)
§1.63(d)) (for continuation/divisional with Box 17 completed)	14. Statement(s) Statement filed in prior application, Statement(s) Status still proper and desired
[Note Box 5 below]	(PTO/SB/09-12)
i. DELETION OF INVENTOR(S)	15. Certified Copy of Priority Document(s)
Signed statement attached deleting inventor(s) named in the prior application,	(if foreign priority is claimed)
see 37 C.F.R. §§1.63(d)(2) and 1.33(b).	5-7
5. Incorporation By Reference (useable if Box 4b is checked) The entire disclosure of the prior application, from which a	16. Other: Priority Claim of U.S. Provisional Application No. 60/247.373 filed November 9, 2000,
copy of the oath or declaration is supplied under Box 4b, is	No. 80/247,373 filed November 9, 2000.
considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.	
opplication and to horsely independed by totological stations.	
	NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY
	*NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F. R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).
17. If a CONTINUING APPLICATION, check appropriate box, and su	
Continuation Divisional Continuation	-in-part (CIP) of prior application No:/
Prior application information: Examiner	Group/Art Unit:
18. CORRESP	PONDENCE ADDRESS
Customer Number or Bar Code Label (Insert Customer No. or Attac	th bar code label here) or Correspondence address below
Name Gregg C. Benson	
Address Pfizer Inc.	
Address Patent Department, MS 4159, Eastern Point Road	
City Groton State	CT Zip Cod e 06340
Country United States Of America Telephone	1-(860)-441-4901 Fax 1-(860)-441-5221
	Registration No. (Attorney/Agent) 36,647
Signature Supply Kaymer	Date 11 /9 /01
. 1	

PTO/SB/17(2/98)
Approved for use through 09/30/2000,
OMB 0651-0032 Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

- 6									OWB 00		Complete if Known	5. DEFARIMEN	TOP COMMERCE	
= 2	_						Applic	Application Number To be assigned						
= a	F	ᄔ	TRANSMITTAL				Applic	auonnu	midei		To be assigned			
S.							Filing	Date			Concurrently herewith			
= : '	Patent fee Thes	fees are subject to annual revision on October 1. hese are the fees effective October 1,, 2001.						lamed Ir	ventor		Tessa A. Castleberry, et al			
Shar Entity payments must be supported by a small entity statement, otherwise large entity fees must be paid. See Forms PTO/SB/09-12.							Exam	iner Nam	пе		To be assigned			
O(I IOI W)	se large	-		.R. §§ 1.27			Groun	/Art Unit			To be assigned			
Total Am	ount of				40.00			ey Dock			PC10893AGPR			
		_		PAYMENT		one)	_	FEE CALCULATION (continued)						
1. 🛛						zed to charge	3 ADDI	TIONAL	FEES	FEE OF	LCGLATION (continued			
						ayments to:		Entity		l Entity				
Deposit Account	16-144					To the state of th	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	n	Fee Paid	
Number							- (
Deposit Account Name	Pfizer I	nc					105	130	205	65	Surcharge – late fee or	oath		
1401110							1							
				☐ Chi	arge the	Issue Fee Set in	127	50	227	25	Surcharge-late provisio cover sheet	nal filing fee or	· 🗀	
37 Fee	Require §§ 1.1.6	d Und and 1	er .17.	37 of t	C.F.R. § he Notic	1 1.8 at the Mailing e of Allowance	139	130	139	130	Non-English specification	n		
109							147	2,520	147	2,520	For filing a request for re	eexamination		
2.	Payment	Encl	osed:				112	920*	112	920*	Requesting publication	of SIR prior to		
Q D	Check		Mone	y Order		ther	113	1,840*	113	1,840*	Examiner action Requesting publication Examiner action	of SIR after		
12.2			FEE C	CALCULAT	ION		115	110	215	55	Extension for reply within	in first month		
1. BASIC F	ILING FE	E					116	400	216	200	Extension for reply within	n second		
Large Ent	c						117	920	217	460	Extension for reply within	n third month		
Fee Fe			Entity Fee (\$)	Fee Desc	ription	Fee Paid	118	1,440	218	720	Extension for reply with			
1004	40 20		370	Utility filin	g fee	740 00	128	1,960	228	980	Extension for reply within	n fifth month		
106 3	30 20	16	165	Design fili	ng fee		119	320	219	160	Notice of Appeal			
107 5	10 20	7	255	Plant filing	g fee		120	320	220	160	Filing a brief in support	of an appeal		
108 7-	40 20	18	370	Reissue fi	ling fee		121	280	221	140	Request for oral hearing	r		
114 1	60 21	4	80	Provision	al filing f	ee	138	1,510	138	1,510	Petition to institute a pul proceeding	olic use		
SUBTOTAL (1) (\$) 740 00						140	110	240	55	Petition to revive - unavoidable				
2. EXTRA CLAIM FEES						141	1,280	241	640	Petition to revive - unintentional				
				Extra Claims	Fee t		142	1,280	242	640	Utility issue fee (or reiss			
Total Claims	18] -2	···- [0		8 = 0	143	460	243	230	Design issue fee			
Independent Claims	3] - :	3**= [0	× e	34 = 0	144	620	244	310	Plant issue fee			
Multiple Depa	endent				28	80 = 0	122	130	122	130	Petitions to the Commis	sioner		
** or number		s <i>ly pa</i> mall E		eater; For F	Re/ssues	s, see below	123	50	123	50	Petitions related to provi	isional		
Fee Fe	e Fe	e	Fee	Fee Des	cription		126	180	126	180	Submission of Information	on Disclosure		
	18 20		(\$)	Claims in	excess	of 20	581	40	581	40	Statement Recording each patent a	assignment per	· —	
102	84 20	2	42	Independe	ent claim	ns in excess of 3	146	740	246	370	property (times number of properties) Filing a submission after final rejection		一	
104 2	80 20	4	140	Multiple de	epender	nt claim, if not paid	149	740	249	370	For each additional inve examined (37 CFR 1.12	(37 CFR 1.129(a)) For each additional invention to be		
109 8	34 20	9	42	**Reissue original		ndent claims over	Other F	Other Fee (specify)						
110 1	18 21	0	9	**Reissue over one	claims i	in excess of 20 and tent	Other F	ee (specif	y)					
			SUBTO	_	(\$)	0	*Reduce	ed by Basi	ic Filing F	ee Paid	SUBTOTAL	(3) (\$)	0	
SUBMITTED BY										Complete (if Applicab	le)			
Type or Printed Name Gregory P. Raymer						,	Reg. Number	36,647						
Signature				Hur	_	Kaymer	Date		11/9	01	Deposit Account User ID	16-1445		

Thereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Box SEQUENCE, Director – U.S. Patent and Trademark Office, Washington, D.C. 20231 on this 9th day of November, 2001.

Зу	Danna L. Miller
	(Signature of person mailing) Deanna L. Miller
	(Typed or printed name of person)
	(Typed of printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Tessa A. Castleberry, et al :

APPLICATION NO.: To be assigned

: Examiner: To be assigned

FILING DATE: Concurrently herewith

: Group Art Unit: To be assigned

TITLE: The Canine Androgen Receptor

Box SEQUENCE

Director - U.S. Patent and Trademark Office

Washington, D.C. 20231

STATEMENT REGARDING SUBMISSION OF SEQUENCE LISTING UNDER 37 C.F.R. §1.821(f)

I hereby state that the information recorded in computer readable form is identical to the written sequence listing.

Respectfully submitted,

Gregory P. Raymer

Attorney for Applicant(s) Reg. No. 36,647

Pfizer Inc. Patent Department, MS 4159 Eastern Point Road Groton, Connecticut 06340 (860) 715-5746